clinical trial · NCT01026194
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
Type 2 Diabetes MellitusPlacebo / Teneli (Teneligliptin) + pio (pioglitazone)Teneli / Teneli + pio
brief summary
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with thiazolidinedione with an extension treatment for up to 52 weeks.
started
Dec 1, 2009
primary completion
Jun 1, 2011
completion
Jun 1, 2011
last updated
Jan 5, 2026
official title
A Phase III Study of MP-513 in Combination With Thiazolidinedione in Japanese Patients With Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol